Abstract: Novel mono-azide substituted rylene-imide derivatives, their use in methods for the detection of analytes and reagents kits for the detection of analytes comprising said novel mono-azide substituted rylene-imide derivatives.

Abstract: The present disclosure provides compounds that may be used as chromogens, fluorochromes, or as both. Said compounds may further be used as substrate for at least one enzyme, wherein said enzyme is capable of processing an aromatic amine group (—NH2), an aromatic hydroxyl group (—OH), or an aromatic phosphate group (—PO4). Furthermore, the present disclosure also provides methods for precipitating said compounds as well as methods for detecting a target using said compounds. Even further, kits comprising said compounds are disclosed. Said compounds may be used in any method utilizing a fluorochrome, a chromogen, or both.

Abstract: The present invention relates to a novel quinacridine derivative and an organic electronic device using the same.

Abstract: Disclosed are new selectively functionalized rylene imides and diimides that can exhibit desirable electronic properties and can possess processing advantages including solution-processability and/or good stability at ambient conditions.

Abstract: Compounds of the general formula (I) and compounds of the general formula (II) Use of compounds (I) or (II) as visible or invisible markers, for staining materials, in the laser welding of materials, for detecting bases, acids or pH changes, as a dispersing assistant, pigment additive for organic pigments and intermediates for the production of pigment additives, in heat management or energy management, in photovoltaics or in optical data storage.

Abstract: The present invention relates to liquid-crystalline rylenetetracarboxylic acid derivatives, to processes for their preparation and to their use as n-type organic semiconductors for producing organic field-effect transistors and solar cells.

Abstract: The present invention relates to novel organic electroluminescent compounds, and organic electroluminescent devices employing the same as electroluminescent material. Specifically, the organic electroluminescent compounds according to the invention are characterized in that they are represented by Chemical Formula (1): wherein, A and B independently represent CR7 or N, provided that both A and B cannot be CR7 or N at the same time; and X is O or S.

Abstract: Lyotropic chromophoric compounds comprised of a naphthalimide derivative, a perylene-3,4-dicarboxylic imide derivative, or a perylenetetracarboxylic diimide derivative are described. The compounds can be used to form liquid crystal systems possessing high quality optical properties. The resulting liquid crystal systems are readily applied onto a substrate to obtain optically isotropic or anisotropic, at least partially crystalline films applicable in various fields.

Abstract: Rylenetetracarboximides of the general formula I in which the variables are defined as follows: R are identical or different radicals: hydrogen; alkyl, cycloalkyl, aryl or hetaryl, each substituted if desired; R? are identical or different radicals: hydrogen; aryloxy, arylthio, hetaryloxy or hetarylthio, each substituted if desired; n is 1 or 2, and also a process for preparing the rylenetetracarboximides I and their use for coloring high molecular weight organic and inorganic materials, for preparing aqueous polymer dispersions which absorb in the near infrared region of the electromagnetic spectrum, for producing markings and inscriptions which absorb infrared light and are invisible to the human eye, as infrared absorbers for heat management, as IR laser beam-absorbing materials in fusion treatment of plastics parts, and also as active components in photovoltaics.

Abstract: The present invention relates to compositions and methods of using free radical scavengers with reduced 1O2 generation. In certain embodiments, these compositions and methods of use relate to fullerene-derived ketolactams and fullerene-derived keto lactam derivatives, fullerene derivatives, and/or fullerenes. In yet other embodiments, the invention relates to cosmetic or dermatological compositions comprising said free radical scavengers with reduced 1O2 generation.

Abstract: Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 5-substituted 2-aminopyridine compound.

Abstract: A method for preparing a perylene pigment or perinone pigment involves a condensation reaction between perylene tetracarboxylic acid or naphthalene tetracarboxylic acid, or anhydrides or imides thereof, and amines in the presence of certain metal catalysts, such as ammonium molybdate, molybdenum oxide, and metal carbonyls, such as hexacarbonylmolybdenum, titanium carbonyl, iron carbonyls, and the like. The use of these catalysts provides various advantages, including the reduction of the amount of the catalyst, while achieves high yields, the lowering of reaction temperatures, and the reduction of insoluble sludge in the reaction mixture, thereby making the reaction operation easier and reducing the amounts of hazardous wastes containing heavy metals.

Abstract: This invention is directed to functionalized higher diamondoids having at least one functional group. Preferably these derivatives have the following Formula I: wherein D is a higher diamondoid nucleus and wherein R1, R2, R3, R4, R5 and R6 are independently selected from a group consisting of hydrogen and functional groups, provided that there is at least one functional group on the derivative. The functionalized higher diamondoid compounds may also be of the formula D—L—(D)n wherein D is a higher diamondoid nucleus and L is a linking group and n is 1 or more. The functionalized higher diamondoid compounds additionally may be of the formula R38—D—D—R39 wherein D is a higher diamondoid nucleus and R38 and R39 are substituents.

Abstract: The present invention relates to the use of compounds of the general formula (I) in which the variables are each defined as follows: X are joined to one another with formation of a six-membered ring to give a radical of the formula (x1), (x2) or (x3) both are each a —CWWM radical; Y one of the two radicals is either a radical of the formula (y1) -L-NR1R2??(y1) or a radical of the formula (y2) -L-Z—R3??(y2) and the other radical is hydrogen; are joined to one another with formation of a six-membered ring to give a radical of the formula (y3) or (y4) or both are hydrogen; W are each independently O or S; W? is O, S or N—R?, with the proviso that at least one of the variables W or W in the general formula I is defined as S; R, P, B, A, D, M, L, Z, R1, R2, R3 and R? are each defined as specified in the description; m is 1, 2, 3 or 4; n is 0, 2 or 4 when m=1, 2 or 3; is 0, 2, 4 or 6 when m=4; p is 0, 2 or 4 when m=1, 2 or 3, where n+p=0, 2 or 4; is 0, 2, 4 or 6 whe

Abstract: A process for preparing quaterrylene-3,4:13,14-tetracarboximides of the general formula I in which R, R? are each independently hydrogen or optionally substituted C1-C30-alkyl, C5-C8-cycloalkyl or aryl or hetaryl; which comprises reacting a perylene-3,4-dicarboximide of the general formula IIa in the presence of a base-stable, high-boiling, organic solvent and of an alkali metal base or alkaline earth metal base, with a perylene-3,4-dicarboximide of the general formula IIb in which X is hydrogen, bromine or chlorine.

Abstract: Compounds of formula: are disclosed. In these compounds is a heterocyclic ring. The compounds are useful as analgesics, anti-pruritics, anti-diarrheal agents, anticonvulsants, antitussives, anorexics/antiobesity agents and as treatments for hyperalgesia, drug addiction, respiratory depression, dyskinesia, pain (including neuropathic pain), irritable bowel syndrome and gastrointestinal motility disorders.

Abstract: The invention provides materials and methods for making anisotropic solids which may be in the form of films, layers, shaped elements, and other shaped articles. The methods provide anisotropic solids without the need for rolling, rubbing, or stretching to impart orientational alignment of the molecules of the solid. The methods employ organic or organometallic compounds which are soluble orienting molecules. The solvent or solvent system must be sufficiently volatile to be removed without disruption of the molecular orientation. The soluble orienting molecules include those containing one or more hydrophilic and/or ionic groups and the solvent or solvent system can be a polar organic solvent or solvent system or an aqueous solvent or solvent system. The invention also provides novel compounds having quaterrylene, perylene and naphthalene ring systems carrying one or more hydrophilic and/or ionic groups.

Abstract: The present invention provides novel methods for preparing 5-(trifluoromethoxy)-1H-3-indazolecarboxylic acid (3), which is a useful precursor for the preparation of bicyclic-5-trifluoromethoxy-1H-indazole-3-carboxylic acid amides of Formula (1). Compounds of Formula (1) are active as agonists and partial agonists of the nicotinic ?-7 receptor and are being studied for their use in the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain, such as for the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders. The present methods are useful for preparing compound (3) on scale up levels.

Abstract: A star-shaped oligothiophene-arylene derivative in which an oligothiophene having p-type semiconductor characteristics is bonded to an arylene having n-type semiconductor characteristics positioned in the central moiety of the molecule and forms a star shape with the arylene, thereby simultaneously exhibiting both p-type and n-type semiconductor characteristics. Further, an organic thin film transistor using the oligothiophene-arylene derivative. The star-shaped oligothiophene-arylene derivative can be spin-coated at room temperature, leading to the fabrication of organic thin film transistors simultaneously satisfying the requirements of high charge carrier mobility and low off-state leakage current.

Abstract: The present invention relates to heptarylene- and octarylenetetracarboximides of the general formula (I) to precursors thereof or mixtures thereof, and to processes for their preparation and to their use.

Abstract: The invention concerns a compound of formula (I): Wherein A, l, m, n, R1 and R2 are as defined herein. The compounds of this invention are useful as medicaments, particularly, in the treatment of disorders improved by modulation of the histamine H3 receptor.

Abstract: The present invention relates to processes for preparing pentarylene- and hexarylenetetracarboximides of the general formula (I) or (Ia) or mixtures thereof, to pentarylene and hexarylenetetracarboximides having a high degree of substitution, and to their use.

Abstract: The present invention relates to a benzenesulfonamide derivative of formula (I), which is useful as an active ingredient of pharmaceutical preparations. The benzenesulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders. In said formula, X represents O or S; R4 represents formulae (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), the other substituents are as defined in claim 1.

Abstract: The invention provides 8-azabicyclo[3.2.1 ]octyl intermediates useful for the preparation of 5-HT4 receptor agonist compounds. The invention also provides processes for the preparation of such useful intermediates.

Abstract: Dibenzorylenetetracarboximides of the general formula I in which the variables are each defined as follows: R? are identical or different radicals: hydrogen; optionally substituted aryloxy, arylthio, hetaryloxy or hetarylthio; R are identical or different radicals: hydrogen; optionally substituted C1-C30-alkyl, C3-C8-cycloalkyl, aryl or hetaryl; m, n are each independently 0 or 1.

Abstract: Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.

Abstract: Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis wherein variables A and B are defined herein.

Abstract: Novel mono-azide substituted rylene-imide derivatives, their use in methods for the detection of analytes and reagents kits for the detection of analytes comprising said novel mono-azide substituted rylene-imide derivatives.

Abstract: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein Z, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: The present invention relates to a novel quinacridine derivative and an organic electronic device using the same.

Abstract: This invention provides for labeling reagents, labeled targets and processes for preparing labeling reagents. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes. These labeling reagents are useful for labeling probes or targets, including nucleic acids and proteins. These reagents can be usefully applied to protein and nucleic acid probe based assays. They are also applicable to real-time detection processes.

Abstract: To provide a material for an organic light emitting device showing a light emission hue with an extremely good purity and outputting light having high luminance and a long lifetime with high efficiency, the present invention relates to a fused heterocyclic compound having at least one partial structure represented by the following general formula [1].

Abstract: 1,6,9,14-Tetrasubstituted terrylenetetracarboxylic diimides are particularly useful for absorbing and emitting in the long-wavelength red and near infrared region of the electromagnetic spectrum.

Abstract: Ditopic molecules in the form of linear reaction templates have been used to construct ladder-like hydrocarbons known as [n]-ladderanes (n=3,5). The templates assemble and position reactant molecules in the solid state by way of hydrogen bonds for [2+2] photodimerization. The products, which are based on recently identified naturally occurring frameworks, form stereospecifically, in gram quantities, and in quantitative yield. The control of reactivity achieved using linear templates provides a basis for the development of molecular tools, termed assemblers, that could be used to manufacture, with atomic-level precision, a wide range of products (e.g. molecular nanostructures) with unique properties.

Abstract: The present invention relates to a process for producing a substrate coated with rylenetetracarboximides, in which a substrate is treated with an N,N?-bisubstituted rylenetetracarboximide and the treated substrate is heated to a temperature at which the N,N?-bisubstituted rylenetetracarboximide is converted to the corresponding N,N?-unsubstituted compound. The present invention further relates to semiconductor units, organic solar cells, excitonic solar cells and organic light-emitting diodes which comprise a substrate produced by this process. The present invention further relates to a process for preparing N,N?-unsubstituted rylenetetracarboximides, in which the corresponding N,N?-bisubstituted rylenetetracarboximides are provided and heated to a temperature at which these compounds are converted to the corresponding N,N?-unsubstituted compounds.

Abstract: A benzoterrylene of Formula (I): wherein at least one of the pairs R4-R5, R6-R7, R10-R11, and R12-R13 is a ring structure selected from the group consisting of Formulas A, B, and C: wherein Y1 through Y4 are each independently selected from O and NR16; and R1 through R16 are as disclosed herein. The benzoterrylenes are useful as lightfast colorants with high fluorescence quantum yields. Also disclosed are methods of making and using the benzoterrylenes.

Abstract: 3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Such compounds are useful for modulating activity of a 5-HT1A receptor (agonizing or antagonizing) in a patient. These compounds are further useful for inhibiting binding to a serotonin receptor. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.

Abstract: A process for preparing quaterrylene-3,4:13,14-tetracarboximides of the general formula I in which R, R? are each independently hydrogen or optionally substituted C1-C30-alkyl, C5-C8-cycloalky or aryl or hetaryl; which comprises reacting a perylene-3,4-dicarboximide of the general formula IIa in the presence of a base-stable, high-boiling, organic solvent and of an alkali metal base or alkaline earth metal base, with a perylene-3,4-dicarboximide of the general formula IIb in which X is hydrogen, bromine or chlorine.

Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions. The invention also relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

Abstract: Rylene derivatives of the general formula I in which the variables are each defined as follows: X are joined to one another with formation of a six-membered ring to give a radical of the formula (a), (b) or (c) are both a —COOM radical; are both hydrogen or one of the two radicals is hydrogen and the other radical is halogen or a radical of the formula (d) Y are joined to one another with formation of a six-membered ring to give a radical of the formula (a) when one of the two X radicals is hydrogen and the other X radical is halogen or a radical of the formula (d) or when both X radicals are hydrogen or together are a radical of the formula (a), (b) or (c); are joined to one another with formation of a six-membered ring to give a radical of the formula (b) when one of the two X radicals is hydrogen and the other X radical is halogen or a radical of the formula (d) or when both X radicals are hydrogen or a —COOM radical or together are a radical of the formula (c); are joined to one anot

Abstract: Compounds that are useful in compositions for flat panel displays, for example, are provided. The compounds provided are polar, and are useful in low threshold voltage mixtures. The compounds provided have the general structure: CpCOCH2[A]nZ1[B]mZ2PhX1X2Y, where CpCOCH2 is the structure: A and B are independently in each instance selected from the group consisting of 1,4-cyclohexane, 1,4-phenyl, 1,3-dioxan-5,2-diyl; pyridine-5,2-diyl; and pyrimidin-5,2-diyl; n and m are independently in each instance 0, 1 or 2; Z1 and Z2 are independently a single bond, —(CH2)2—, CF2O, OCF2, CH2O, OCH2, —C?C—, COO, OOC; and Y is selected from the group consisting of: F, Cl, CN, OCH2F, CHF2, OCF3, and CF3.

Abstract: Rylenetetracarboximides of the general formula I in which the variables are defined as follows: R are identical or different radicals: hydrogen; alkyl, cycloalkyl, aryl or hetaryl, each substituted if desired; R? are identical or different radicals: hydrogen; aryloxy, arylthio, hetaryloxy or hetarylthio, each substituted if desired; n is 1 or 2, and also a process for preparing the rylenetetracarboximides I and their use for coloring high molecular weight organic and inorganic materials, for preparing aqueous polymer dispersions which absorb in the near infrared region of the electromagnetic spectrum, for producing markings and inscriptions which absorb infrared light and are invisible to the human eye, as infrared absorbers for heat management, as IR laser beam-absorbing materials in fusion treatment of plastics parts, and also as active components in photovoltaics.

Abstract: Rylene dyes of the general formula I where the variables are defined as follows: R is hydrogen; optionally substituted C1-C30-alkyl, C5-C8-cycloalkyl, aryl or hetaryl; R? is bromine; cyano; —NR32; optionally substituted aryloxy, arylthio, hetaryloxy or hetarylthio; optionally substituted C3-C18-alk-1-ynyl; X, Y are both hydrogen or together are a radical of the formula Ia n is 2, 3, 4 or additionally 1 when X and Y are a radical of the formula Ia; n? is from 1 to 4; m is from 0 to 6.

Abstract: Rylene derivatives of the general formula I in which the variables are each defined as follows: Rylene is a polycyclic conjugated ring system which comprises at least one perylene unit may comprise heteroatoms as ring atoms, may be functionalized by moieties comprising —CO— groups and/or may bear further substituents other than the A radicals; A is a radical of the formula X is oxygen or sulfur; R are identical or different radicals: optionally substituted alkyl, cycloalkyl, aryl, hetaryl, —U-aryl where U is an —O—, —S—, —NR2—, —CO—, —SO— or —SO2— moiety, or C1-C12-alkoxy, C1-C6-alkylthio, —C?CR2, —CR2?CR22, hydroxy, mercapto, halogen, cyano, nitro, —NR3R4, —NR3COR4, —CONR3R4, —SO2NR3R4, —COOR3 or —SO3R3; R? are identical or different radicals: hydrogen or one of the R radicals; R2 is hydrogen or alkyl, where the R2 radicals may be the same or different when they occur more than once; R3, R4 are each independently hydrogen; optionally substituted alkyl, aryl or hetaryl; n is from 1 to

Abstract: The present invention relates to a method of determining voltage changes, e.g. in cell membranes, by means of a voltage-sensitive dye.

Abstract: A process for preparing terylene-3,4:11,12-tetracarboximides I where the variables are each defined as follows: R, R? are each independently hydrogen; if desired substituted alkyl or cycloalkyl; R1 is hydrogen or alkyl; R2 is hydrogen; alkyl; if desired substituted aryl or hetaryl, by reacting a perylene-3,4-dicarboximide II in the presence of a base-stable, high-boiling organic solvent and of an alkali metal or alkaline earth metal base, with a naphthalene-1,8-dicarboximide III in which X is hydrogen, bromine or chlorine.

Abstract: Compounds of the following structure are described: wherein R1-R6, R11, R12, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Abstract: This invention relates to a new process for the preparation of novel substituted haloarene compounds of the formula I or IV: respectively, wherein R1, R2, R3, R4, R5, X, and Y are as defined herein, that comprises a novel and efficient selective mono-lithiation of a dihaloarene of the formula II or V: respectively, by an organo-lithium compound in the presence of a carbonyl reactant of the formula III: wherein R1 and R2 are as defined herein. In the process of the instant invention, the newly formed lithiated haloarene is sequentially quenched in situ by the carbonyl reactant to form said substituted haloarene. The process is suitable for batch or continuous flow systems.

Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR? retinoid receptors.

Abstract: The inventors have purified the fluorescent product in the hydroethidine-based supeorxide detection assays and further identified the product as 2-hydroxyethidium. Methods for synthesizing 2-hydroxyethidium and for detecting and quantifying superoxide are provided.